New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 17, 2014
07:09 EDTGILDGilead consensus estimates likely to move higher, says Piper Jaffray
Piper Jaffray attributes the recent pullback in shares of Gilead to the company's slowing earnings growth, which it says is "inevitable given the strong Sovaldi launch." Piper expects consensus estimates for Gilead to move higher in the coming months, making the stock more of a value name. The firm also thinks Gilead has "multiple levers to create shareholder" and it reiterates an Overweight rating on the name with a $105 price target.
News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 18, 2014
09:35 EDTGILDActive equity options trading
Active equity options trading according to Track Data: AAPL FB TSLA PBR RAD AMAT NFLX GILD KMI TWTR
December 17, 2014
09:41 EDTGILDActive equity options trading
Subscribe for More Information
December 16, 2014
16:00 EDTGILDOptions Update; December 16, 2014
iPath S&P 500 VIX Short-Term Futures up 1.55 to 34.60. Option volume leaders: AAPL TSLA TWTR AMZN FB C GILD BAC NFLX AA MGM MCD according to Track Data.
December 12, 2014
09:35 EDTGILDActive equity options trading
Subscribe for More Information
December 11, 2014
16:01 EDTGILDOptions Update; December 11, 2014
Subscribe for More Information
11:55 EDTGILDGilead shares look cheap, poised for growth, Barron's says
Subscribe for More Information
07:54 EDTGILDGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
December 10, 2014
15:59 EDTGILDGilead sued by SEPTA over price of Hep C drug Sovaldi, WSJ reports
Subscribe for More Information
December 9, 2014
09:38 EDTGILDActive equity options trading
Subscribe for More Information
08:38 EDTGILDGilead price target raised to $130 from $110 at Argus
Subscribe for More Information
December 8, 2014
16:00 EDTGILDOptions Update; December 8, 2014
Subscribe for More Information
10:02 EDTGILDGilead presents follow-up data from Zydelig registrational studies
Subscribe for More Information
December 5, 2014
09:36 EDTGILDActive equity options trading
Subscribe for More Information
07:37 EDTGILDGilead price target raised to $121 from $110 at JPMorgan
JPMorgan raised its price target for Gilead shares to $121 saying the company's potential cash flow generation is "immense" and provides "significant strategic flexibility." The firm estimates Gilead can generate more than $30B in cash in the next two years and $80B-plus over the next five years. It keeps an Overweight rating on the stock.
December 4, 2014
09:01 EDTGILDVA negotiated $594 per dose price for Gilead HCV treatment
A Veterans Health Administration official told a Senate committee yesterday that Veterans' Affairs has "moved rapidly to deploy new, more effective, less toxic HCV treatments and has been able to negotiate significant discounts for these newer therapies." The agency negotiated a price of $594 per dose for Gilead's (GILD) Hepatitis C virus drug Sofosbuvir, below the commercial price of $1,000 per dose, VHA Chief Consultant for Pharmacy Benefits Management Michael Valentino told the Senate's Committee on Veterans' Affairs. The agency also received a $413 per dose price for Johnson & Johnson's (JNJ) Simeprevir, below the commerical price of $790. The VA has approximately 174,000 veterans in care with HCV, making it the largest single HCV provider in the U.S., Valentino pointed out. He added, "Like the rest of the country, VA has treated only a portion of Veterans for HCV because treatment and cures have been difficult to achieve due to low efficacy and high toxicity of standard drug therapies." Reference Link

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use